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Abstract
Background: Saliva and urine have been used for arthropod-borne viruses molecular detection but not yet for
chikungunya virus (CHIKV). We investigated the use of saliva and urine for molecular detection of CHIKV during the
French Polynesian outbreak.
Methods: During the French Polynesian chikungunya outbreak (2014–2015), we collected the same day blood and
saliva samples from 60 patients with probable chikungunya (47 during the 1st week post symptoms onset and 13
after), urine was available for 39 of them. All samples were tested using a CHIKV reverse-transcription PCR.
Results: Forty eight patients had confirmed chikungunya. For confirmed chikungunya presenting during the 1st
week post symptoms onset, CHIKV RNA was detected from 86.1 % (31/36) of blood, 58.3 % (21/36) of saliva and 8.
3 % (2/24) of urine. Detection rate of CHIKV RNA was significantly higher in blood compared to saliva. For
confirmed chikungunya presenting after the 1st week post symptoms onset, CHIKV RNA was detected from 8.3 %
(1/12) of blood, 8.3 % (1/12) of saliva and 0 % (0/8) of urine.
Conclusions: In contrast to Zika virus (ZIKV), saliva did not increased the detection rate of CHIKV RNA during the
1st week post symptoms onset. In contrast to ZIKV, dengue virus and West Nile virus, urine did not enlarged the
window of detection of CHIKV RNA after the 1st week post symptoms onset. Saliva can be used for molecular
detection of CHIKV during the 1st week post symptoms onset only if blood is impossible to collect but with a
lower sensitivity compared to blood.
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Background
French Polynesia (FP), south Pacific, is a high endemic
area for arthropod-borne viruses (arboviruses) [1]. Until
2013, dengue virus (DENV) (arbovirus of the genus
Flavivirus) has been the only arbovirus detected in FP,
causing multiple outbreaks from the 1960s [2]. Zika virus
(ZIKV) (arbovirus of the genus Flavivirus), emerged in FP
in 2013 causing an outbreak from October 2013 to April
2014 [3, 4]. Chikungunya virus (CHIKV) (arbovirus of the
genus Alphavirus) [5], emerged in the Pacific in 2011 and
subsequently spread throughout the region [6]. A CHIKV
outbreak occurred in FP from October 2014 to March
2015 [7] with an estimate of 66,000 cases (about 25 % of
the population) [6].
During the FP ZIKV outbreak, we developed molecu-
lar ZIKV detection on saliva as an alternative sample to
blood [8]. The ability to detect ZIKV was higher in saliva
compared to blood at the acute phase of the illness. This
protocol was of particular interest when blood was
difficult to collect, especially for children and neonates.
For ZIKV [9–11], DENV [12, 13] or West Nile virus
(WNV) [14, 15], the use of urine for molecular diagnosis
can enlarge the window of detection of these arboviruses.
As alternative sample to blood have been reported to
increase the detection rate or to enlarge the window of
detection of arboviruses, we investigated the use of saliva
and urine for CHIKV molecular detection during the FP
CHIKV outbreak.
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Methods
The study was conducted in FP over a 4 months period
from November 2014 to February 2015, during the FP
CHIKV outbreak.
Patients presenting in our laboratory with a medical
prescription for chikungunya diagnosis were asked to
provide, in addition to blood, saliva and urine sample. A
standardized medical questionnaire form was available
for all patients, it included the numbers of days after
symptoms onset and the main clinical symptoms.
After informed written consent was obtained, blood
was collected by venous puncture, saliva was collected
with dry cotton swabs without transport media (N°
150C, Copan, Brescia, Italy), and urine was collected on
sterile containers without additives. We included in the
study patients with possible chikungunya infection with
both blood and saliva, and if possible urine, samples
collected at the same time.
Case definition for possible and confirmed CHIKV
were defined according the World Health Organization
[16] and European Center for Diseases Prevention and
Control [17] criteria. Possible cases were patient with
clinical criteria of chikungunya (acute onset of fever >
38.5 °C and severe arthralgia/arthritis) not explained by
other medical conditions; confirmed cases were patient
meeting the laboratory criteria [virus isolation or pres-
ence of viral RNA by Reverse Transcription (RT)-PCR]
presence of virus specific IgM antibodies in single serum
sample collected in acute or convalescent stage, four-
fold increase in IgG values in sample collected at least
3 weeks apart), irrespective of the clinical presentation.
According to the French recommendations [18] blood
samples were tested by RT-PCR for patients collected
from days 1 to 4 post symptoms onset (PSO), by RT-PCR
and serology for patients collected from days 5 to 7 PSO
and by serology for patients collected after day 7 PSO. In
order to compare the use of RT-PCR in saliva and urine to
blood, all samples were tested by CHIKV RT-PCR, includ-
ing blood samples collected after day 7 PSO.
For molecular detection of CHIKV, RNA extraction
was performed using the NucliSENS® easyMAG® Sys-
tem (BioMérieux) according to manufacturer’s recom-
mendations. Two hundred μl of serum or 500 μl of
urine were added to 2 ml of lysis buffer, oral swabs
were first vortexed in 2 ml of lysis buffer, then all were
eluted by elution buffer and 5 μl of extracted RNA was
used for amplification on a CFX96 Touch™ Real-Time
PCR detection System (Biorad) using primers/probe
amplification sets specific for CHIKV as previously
reported [7, 19].
Immunoglobulin M (IgM) detection was performed
using Novalisa Chikungunya IgG/IgM μ-capture ELISA
kit (NovaTec Immundiagnostica GmbH, Germany) ac-
cording to the recommendations of the supplier.
Results
Sixty patients were included in the study, of them 48
had confirmed chikungunya (36 presenting during the
1st week PSO and 12 after), 32 infections have been con-
firmed by detection of CHIKV RNA and 16 by detection
of specific IgM antibodies against CHIKV (Table 1).
Blood and saliva were available from all patients.
Urine was available from 39 patients (32 from con-
firmed chikungunya).
Saliva and urines RT-PCR results for patients with
confirmed chikungunya are reported in Tables 2 and 3
respectively.
For confirmed chikungunya presenting during the 1st
week PSO, CHIKV RNA was detected from 86.1 % (31/
36) of blood, 58.3 % (21/36) of saliva and 8.3 % (2/24) of
urine. Detection rate was significantly higher in blood
compared to saliva (Fisher's exact test, p = 0.008), it was
not significantly higher in blood compared to urine
(Fisher's exact test, p = 1) but the number of patients was
too small to observe a significant difference.
Samples testing positive in urine by RT-PCR were
collected on days 3 and 5 PSO.
For confirmed chikungunya presenting after the 1st
week PSO, CHIKV RNA was detected from 8.3 % (1/12)
of blood, 8.3 % (1/12) of saliva and 0 % (0/8) of the urine.
Detection rate was not significantly different when we
compared blood to saliva (Fisher's exact test, p = 0.08) and
urine (Fisher's exact test, p = 0.08).
The proportion of positive RT-PCR saliva samples ac-
cording to the number of days PSO is reported in Fig. 1.
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None of the 12 patients who tested negative by CHIKV-
RT-PCR in blood was positive in saliva and/or urine.
Discussion
Urine and saliva as alternative samples to blood have
been used successfully for molecular arbovirus detection
[8–15, 20–26].
During the FP ZIKV outbreak, the use of saliva in-
creased the detection rate of ZIKV RNA at the acute
phase of the disease [8], saliva was also used to detect
ZIKV from an Australian traveller returning from
Indonesia [20]. Detection of dengue virus (DENV) RNA
in saliva was reported [12, 21]. CHIKV RNA and
infectious CHIKV in saliva were found only in patients
with gingivorrhagia [22]. In our study, none of the 22
patients with saliva testing positive for CHIKV reported
hemorrhagic manifestations, nevertheless we cannot
exclude that subclinical gingivorrhagia were responsible
of positivity of saliva due to contamination by viremic
blood. In contrast to ZIKV [8], CHIKV detection in sal-
iva did not increased the rate of molecular detection of
CHIKV. As saliva was positive in 58.3 % of confirmed
chikungunya presenting during the 1st week PSO, saliva
can be of interest for molecular CHIKV detection only if
blood samples are impossible to collect, especially if col-
lected from the first 3 days PSO.
Arbovirus detection in urine was reported at the acute
and late phase of dengue [12, 13, 23], WNV [14, 15],
CHIKV [26] and ZIKV infection [9–11, 24, 25]; and dur-
ing Japanese encephalitis [27] and yellow fever [28] in-
fections. The main interest of urine was to enlarge the
window of detection for DENV [12, 13], WNV [14, 15]
and ZIKV [9–11, 25] after the acute phase. CHIKV was
detected in urine of experimentally infected mice at day
30 post infection, after CHIKV clearance in blood [29].
In our study, the two urines samples testing positive for
CHIKV were collected during the 1st week PSO and all
samples collected after tested negative.
Conclusions
According to our results, saliva cannot replace blood for
molecular detection of CHIKV. Saliva specimen can be
used only during the 1st week PSO if blood is impossible
to collect and with the restriction that the sensitivity is
low. In contrast to DENV, WNV and ZIKV, urine does
not enlarge the window of detection of CHIKV RNA. If
saliva and urine are of great interest for the detection of
ZIKV RNA, blood remains the sample of choice for
CHIKV, DENV and WNV RNA detection.
These results should be confirmed on a larger study.
Fig. 1 Proportion of positive samples according to the number of days after symptoms onset for the 60 patients with both blood (blue) and
saliva (red) samples tested by ZIKV RT-PCR
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